Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The Increlex (mecasermin) FDA label, which covers native rhIGF-1 in pediatric severe primary IGFD, is the closest human reference and informs the contraindications below
Estudios clnicos han demostrado que permiten perder al menos un 5 % del peso corporal, y muchos pacientes logran reducciones mayores, especialmente si combinan el tratamiento con dieta y ejercicio
Instrumental parameters were tuned for each sample with GSH or GSSG
The figure printed on each batch's Certificate of Analysis reflects the purity value recorded in the laboratory for that specific batch
US$ 29.63
US$ 27.98
US$ 25.91
US$ 26.43
